[{"orgOrder":0,"company":"Orpha Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Carbohydrate","year":"2017","type":"Inapplicable","leadProduct":"L-Fucose","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orpha Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orpha Labs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Orpha Labs \/ Undisclosed"},{"orgOrder":0,"company":"AUG Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"L-Fucose","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"AUG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"AUG Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AUG Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"L-Fucose","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avalo Therapeutics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for L-Fucose

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : The active pharmaceutical ingredient (API) in AVTX-803 is L-fucose an oral formulation of L-fucose that enhances fucosylation of proteins in the absence of a functioning GDP-fucose transporter, partially restoring protein function.

                          Product Name : Undisclosed

                          Product Type : Carbohydrate

                          Upfront Cash : Inapplicable

                          August 02, 2022

                          Lead Product(s) : L-Fucose

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AUG Therapeutics

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          AUG Therapeutics

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : L-Fucose is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukocyte-Adhesion Deficiency Syndrome.

                          Product Name : Undisclosed

                          Product Type : Carbohydrate

                          Upfront Cash : Inapplicable

                          July 18, 2022

                          Lead Product(s) : L-Fucose

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Orpha Labs

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Orpha Labs

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : L-Fucose is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Congenital disorder of glycosylation, type 2C.

                          Product Name : Undisclosed

                          Product Type : Carbohydrate

                          Upfront Cash : Inapplicable

                          November 28, 2017

                          Lead Product(s) : L-Fucose

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank